Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T17:33:22.513Z.
Calculation as of: 2026-10-06T17:33:22.513Z.
Quote observation: 2026-10-06T17:29:49.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2100d4567e155cb65401b1d64ef1112e8effddeb5d941ccec26242c7dbad22d6
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Orchestra BioMed Holdings, Inc.
Market Cap
$353.00M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$354.32M
EV/EBIT Ratio
N/A
TTM Avg
55.83x
3Y Avg
55.83x
5Y Avg
55.83x
Market Cap
$352.14M
EV/EBIT Ratio
N/A
TTM Avg
45.54x
3Y Avg
33.14x
5Y Avg
24.49x
Market Cap
$352.74M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Orchestra BioMed Holdings, Inc. (OBIO) | $353.00M | N/A | N/A | N/A | N/A |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $354.32M | N/A | 55.83x | 55.83x | 55.83x |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $352.14M | N/A | 45.54x | 33.14x | 24.49x |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $352.74M | N/A | N/A | N/A | N/A |
| Ocugen, Inc. (OCGN)vs › | $356.07M | N/A | N/A | N/A | N/A |
| Turn Therapeutics Inc. (TTRX)vs › | $357.61M | N/A | N/A | N/A | N/A |
| Embecta Corp. (EMBC)vs › | $359.23M | 6.50x | 5.53x | 9.02x | 8.48x |
| Relmada Therapeutics, Inc. (RLMD)vs › | $347.71M | N/A | N/A | N/A | N/A |
| Opus Genetics, Inc. (IRD)vs › | $359.15M | N/A | N/A | N/A | N/A |
| YD Bio Limited Ordinary Shares (YDES)vs › | $369.74M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
